DOCSLIB.ORG

Confidential: for Review Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Confidential: for Review Only Supplementary material Gut Page 55 of 338 Gut 1 2 3 498 4 Supplementary Figure 1| Overview of the workflow for the multi-omics strategy 5 499 used in this study. Host phenome, serum and faecal metabolomes, and gut 6 500 microbiome of 235 ESRD patients and 81 healthy controls were characterised and 7 501 integrated into a multi-omics dataset. (A) Data types; (B) Differential filtering refers 8 9 502 to statistical significance computation based on differential abundance of features in 10 503 the patient and control groups; (C) Correlation and effect size analyses of multi-omics 11 504 dataset; (D) Predictive model building and clustering of metagenomics species with 12 Confidential: For Review Only 505 13 metabolites into co-abundance based networks; (E) Animal experiments testing the 14 506 effect of ESRD microbiota (left panel), ESRD-associated species (centre panel) and 15 507 probiotics (left panel). 16 508 17 18 509 Supplementary Figure 2| Differences in levels of serum metabolites between 19 510 ESRD patients and healthy controls. (A) Boxplot shows the serum metabolites that 20 511 differ significantly between ESRD patients and healthy controls. Top panel, ESRD 21 22 512 patient-enriched metabolites. Bottom panel, healthy control-enriched metabolites. The 23 513 uremic toxins that are enriched in ESRD patients are highlighted in red. Boxes 24 514 represent the interquartile range between the first and third quartiles and median 25 515 26 (internal line). Whiskers denote the lowest and highest values within 1.5 times the 27 516 range of the first and third quartiles, respectively; dots represent outliers beyond the 28 517 whiskers. (B) Changes in the composition of bile acids in two groups. Average 29 518 relative abundance (normalized from their raw abundance) of 16 bile acids of ESRD 30 31 519 patients and healthy controls are shown. Bottom panel: the ratios of unconjugated vs. 32 520 conjugated bile acids, unconjugated PBA/SBA and conjugated PBA are calculated for 33 521 each individual and compared between patients and controls. Abbreviations of the bile 34 35 522 acids are listed at Online Methods. (C) Correlation analysis of the quantified 36 523 concentrations of five targeted serum uremic toxins and non-targeted abundance in 60 37 524 randomly chosen serum samples (ESRD patients, n=40; and healthy controls, n=20). 38 525 39 40 526 Supplementary Figure 3| Schematic representation of the metabolic pathways of 41 527 the serum uremic toxins and bile acids associated with gut microbiota. (A) 42 528 Production of serum uremic toxins by gut microbiota via degrading diet-originated 43 44 529 aromatic amino acids, polyphenols and choline. (B) Metabolism of bile acids. The key 45 530 enzymes encoded by gut microbes are highlighted by orange boxes, and details are 46 531 shown in online supplementary table 14. 47 48 532 49 533 Supplementary Figure 4| Concentrations of serum uremic toxins and bile acids 50 534 are highly correlated with ESRD-associated clinical parameters. The heatmap 51 535 52 panels show the Spearman correlation coefficient between serum uremic toxins or bile 53 536 acids and ESRD-associated clinical parameters, for which significance levels in 54 537 correlation tests are denoted: +, q < 0.05; *, q < 0.01; **, q < 0.001. Top: all cohort; 55 538 bottom left and right: patients and controls, respectively. Information on metabolites 56 57 539 included in clusters S10, S19, S20, S24, S37, and S38 are provided in online 58 540 supplementary table 5. 59 541 60 https://mc.manuscriptcentral.com/gut Wang X, et al. Gut 2020;0:1–12. doi: 10.1136/gutjnl-2019-319766 Supplementary material Gut Gut Page 56 of 338 1 2 3 542 4 Supplementary Figure 5| Differences in faecal metabolite levels between ESRD 5 543 patients and healthy controls. (A) Boxplot shows the faecal metabolites that differ 6 544 significantly between ESRD patients and healthy controls. The uremic toxins that are 7 545 enriched in ESRD patients and the SCFAs that are prominently enriched in healthy 8 9 546 controls are highlighted in red. (B) Targeted metabolomic profiling of 16 faecal bile 10 547 acids of ESRD patients and healthy controls. Bottom panel: the abundance of total 11 548 PBAs, total SBAs, and the ratio of PBA/SBA are calculated for each individual and 12 Confidential: For Review Only 549 q q 13 compared between patients and controls. Significance levels: ‘*’, < 0.05, ‘+’, < 14 550 0.10. (C) Effect size of faecal metabolites that drive the variance of faecal 15 551 metabolome. 16 552 17 18 553 Supplementary Figure 6| Correlation analysis between serum uremic toxins and 19 554 their faecal precursors. Fitted lines and 95% confidence intervals are shown. 20 555 21 22 556 Supplementary Figure 7| Validation of the ESRD-associated serum (A) and 23 557 faecal metabolites (B) in an independent cohort. Boxplot shows the comparison of 24 558 serum uremic toxins (left panel) and faecal uremic toxin precursors and SCFAs (right 25 559 26 panel). Red boxes, ESRD patients (n = 12); blue boxes, healthy controls (n = 12). 27 560 Significance levels: ‘***’, q < 0.001, ‘**’, q < 0.01, ‘*’, q < 0.05, ‘+’, q < 0.10. 28 561 29 562 30 Supplementary Figure 8| Alteration of microbial taxonomic composition and 31 563 functions in ESRD patients. (A) Shannon’s diversity index of ESRD patients and 32 564 healthy controls. (B-C) Distance-based redundancy analysis (dbRDA) reveals a 33 565 significant difference of gut microbial taxonomic composition (B) and functional 34 35 566 profiles (C) in ESRD patients (n = 223) and healthy controls (n = 69). KEGG 36 567 orthologue (KO)-based and MGS-based Bray-Curtis dissimilarity was used to assess 37 568 the functional and taxonomic difference, respectively. The display is based on sample 38 569 39 scores on the primary constrained axis (CAP1) and primary multidimensional scaling 40 570 (MDS1), see Online Methods for details. 41 571 42 572 43 Supplementary Figure 9| Differences in bacterial species between ESRD patients 44 573 and healthy controls. (A) List of species that were significantly enriched in ESRD 45 574 patients or healthy controls. (B-C) Stratification of patients and healthy controls. The 46 575 20 most discriminant species enriched in ESRD patients (B) or healthy controls (C). 47 48 576 The receiver operating characteristic (ROC) curves for classification of ESRD 49 577 patients and healthy controls are shown; values of the area under the ROC curve 50 578 (AUC) are listed in the right panels. (D-F) Distribution of MGS encoding the key 51 579 52 acetate (D), propionate (E) and butyrate (F) synthesis genes in ESRD patients and 53 580 healthy controls. MGS were grouped in genera. Red colour denotes statistically 54 581 significant abundance difference (q < 0.05). 55 582 56 57 583 Supplementary Figure 10| Differences in microbial functions between ESRD 58 584 patients and healthy controls (A-C) Alterations in microbial pathways and 59 60 https://mc.manuscriptcentral.com/gut Wang X, et al. Gut 2020;0:1–12. doi: 10.1136/gutjnl-2019-319766 Supplementary material Gut Page 57 of 338 Gut 1 2 3 585 functional modules. ( Alterations in gut functional modules involved in amino acid 4 D) 5 586 degradation and bile acid metabolism. Red, ESRD-enriched; cyan, control-enriched. 6 587 7 588 Supplementary Figure 11| The correlation networks in ESRD patients and 8 9 589 healthy controls. (A-C) ESRD-specific (A), control-specific (B) and shared (C) 10 590 correlation networks of the gut MGS, serum and faecal metabolomes. Vertices 11 591 indicate variables and lines indicate significant Spearman’s correlations (|ρ| > 0.35 12 Confidential: For Review Only 592 q 13 and < 0.01). The serum and faecal variables were clustered to simplify the networks. 14 593 (D-E) Number of correlations between serum metabolite clusters and the gut 15 594 microbiota (D) or faecal metabolite clusters (E). The serum metabolite clusters of 16 595 uremic toxins and bile acids are highlighted in red. ( ) The clusters of serum uremic 17 F 18 596 toxins and bile acids correlated to MGSs (listed on the right; unclassified MGS are 19 597 omitted) and faecal metabolites. (G) Conservation of MGS-uremic toxins/SBAs 20 598 correlations in the ESRD and control networks. Correlations that were significant 21 22 599 (|ρ| > 0.35 and q < 0.01) in at least one network (ESRD or control) are shown. ‘**’, P 23 600 < 0.01; ‘***’, P < 0.001. 24 601 25 602 26 Supplementary Figure 12| The effect size of gut microbiota on the host serum 27 603 metabolome in different studies. The approach described in the Methods section 28 604 was used for all studies. 29 605 30 31 606 Supplementary Figure 13| Number of medications used for ESRD patients. 32 607 33 608 Supplementary Figure 14| Distribution of the key synthetases involved in the 34 35 609 biosynthesis of uremic toxins and SBAs. (A) Relative abundance of key synthetase- 36 610 encoding genes in ESRD patients and healthy controls (left panels) and in MGS- 37 611 assigned genes (right panels). The number of synthetase-encoding genes in each MGS 38 612 39 is shown in brackets. Boxes represent the interquartile range between the first and 40 613 third quartiles and median (internal line). Whiskers denote the lowest and highest 41 614 values within 1.5 times the range of the first and third quartiles, respectively, and 42 615 circles represent outliers beyond the whiskers. ( ) Correlations between the 43 B 44 616 abundance of key synthetase-encoding genes and faecal concentrations of 45 617 corresponding metabolites. Best-fit lines and 95% confidence intervals (CI) are 46 618 indicated.
Load more

Recommended publications
  • WO 2018/064165 A2 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
    International Journal of Molecular Sciences Review The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder Piranavie Srikantha and M. Hasan Mohajeri * Department of medicine, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +41-79-938-1203 Received: 27 March 2019; Accepted: 28 April 2019; Published: 29 April 2019 Abstract: New research points to a possible link between autism spectrum disorder (ASD) and the gut microbiota as many autistic children have co-occurring gastrointestinal problems. This review focuses on specific alterations of gut microbiota mostly observed in autistic patients. Particularly, the mechanisms through which such alterations may trigger the production of the bacterial metabolites, or leaky gut in autistic people are described. Various altered metabolite levels were observed in the blood and urine of autistic children, many of which were of bacterial origin such as short chain fatty acids (SCFAs), indoles and lipopolysaccharides (LPS). A less integrative gut-blood-barrier is abundant in autistic individuals. This explains the leakage of bacterial metabolites into the patients, triggering new body responses or an altered metabolism. Some other co-occurring symptoms such as mitochondrial dysfunction, oxidative stress in cells, altered tight junctions in the blood-brain barrier and structural changes in the cortex, hippocampus, amygdala and cerebellum were also detected. Moreover, this paper suggests that ASD is associated with an unbalanced gut microbiota (dysbiosis). Although the cause-effect relationship between ASD and gut microbiota is not yet well established, the consumption of specific probiotics may represent a side-effect free tool to re-establish gut homeostasis and promote gut health.
    [Show full text]
  • The Role of the Intestinal Microbiota in Inflammatory Bowel Disease Seth Bloom Washington University in St
    Washington University in St. Louis Washington University Open Scholarship All Theses and Dissertations (ETDs) 1-1-2012 The Role of the Intestinal Microbiota in Inflammatory Bowel Disease Seth Bloom Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/etd Recommended Citation Bloom, Seth, "The Role of the Intestinal Microbiota in Inflammatory Bowel Disease" (2012). All Theses and Dissertations (ETDs). 555. https://openscholarship.wustl.edu/etd/555 This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Molecular Microbiology and Microbial Pathogenesis Dissertation Examination Committee: Thaddeus S. Stappenbeck, Chair Paul M. Allen Wm. Michael Dunne David B. Haslam David A. Hunstad Phillip I. Tarr Herbert W. “Skip” Virgin, IV The Role of the Intestinal Microbiota in Inflammatory Bowel Disease by Seth Michael Bloom A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May 2012 Saint Louis, Missouri Copyright By Seth Michael Bloom 2012 ABSTRACT OF THE DISSERTATION The Role of the Intestinal Microbiota in Inflammatory Bowel Disease by Seth Michael Bloom Doctor of Philosophy in Biology and Biomedical Sciences Molecular Microbiology and Microbial Pathogenesis Washington University in St. Louis, 2012 Professor Thaddeus S. Stappenbeck, Chairperson Inflammatory bowel disease (IBD) arises from complex interactions of genetic, environmental, and microbial factors.
    [Show full text]
  • Gut Microbiota Analysis UC Davis MMPC - Microbiome & Host Response Core
    D4006- Gut Microbiota Analysis UC Davis MMPC - Microbiome & Host Response Core Contents 1 Methods: 1 1.1 Sequencing . .1 1.2 Data processing . .1 2 Summary of Findings: 2 2.1 Sequencing analysis . .2 2.2 Microbial diversity . .2 2.2.1 Alpha Diversity . .2 2.2.2 Beta Diversity . 10 2.3 Data analysis using taxa abundance data . 13 2.3.1 Stacked bar graphs of Taxa abundances at each level . 14 A Appendix 1 (Taxa Abundance Tables) 30 B Appendix 2 (Taxa removed from filtered datasets at each level) 37 References: 43 Core Contacts: Helen E. Raybould, Ph.D., Core Leader ([email protected]) Trina A. Knotts, Ph.D., Core Co-Leader ([email protected]) Michael L. Goodson, Ph.D., Core Scientist ([email protected]) Client(s): Kent Lloyd, DVM PhD ;MMRRC; UC Davis Project #: MBP-2079 MMRRC strain ID: MMRRC_043603 Animal Information: The strain was donated to the MMRRC by Jonathan Chernoff at Fox Chase Cancer Center. Fecal samples were obtained from animals housed under the care of Jonathan Chernoff at Fox Chase Cancer Center. 1 Methods: Brief Project Description: MMRRC strains are often contributed to the MMRRC to fulfill the resource sharing aspects of NIH grants. Since transporting mice to another facilty often causes a microbiota shift, having a record of the original fecal microbiota from the donor institution where the original phenotyping or testing was performed may prove helpful if a phenotype is lost after transfer. Several MMRRC mouse lines were selected for fecal microbiota profiling of the microbiota. Table 1: Animal-Strain Information X.SampleID TreatmentGroup Animal_ID Genotype Line Sex MMRRC.043603.M4 MMRRC.043603_Hom_M M4 Hom MMRRC.043603 M MMRRC.043603.M5 MMRRC.043603_Hom_M M5 Hom MMRRC.043603 M 1 1.1 Sequencing Frozen fecal or regional gut samples were shipped on dry ice to UC Davis MMPC and Host Microbe Systems Biology Core.
    [Show full text]
  • Protection of the Human Gut Microbiome From
    Protection of the Human Gut Microbiome From Antibiotics Jean de Gunzburg, Amine Ghozlane, Annie Ducher, Emmanuelle Le Chatelier, Xavier Duval, Etienne Ruppé, Laurence Armand-Lefevre, Frédérique Sablier-Gallis, Charles Burdet, Loubna Alavoine, et al. To cite this version: Jean de Gunzburg, Amine Ghozlane, Annie Ducher, Emmanuelle Le Chatelier, Xavier Duval, et al.. Protection of the Human Gut Microbiome From Antibiotics. Journal of Infectious Diseases, Oxford University Press (OUP), 2018, 217 (4), pp.628-636. 10.1093/infdis/jix604. pasteur-02552147 HAL Id: pasteur-02552147 https://hal-pasteur.archives-ouvertes.fr/pasteur-02552147 Submitted on 23 Apr 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License The Journal of Infectious Diseases MAJOR ARTICLE Protection of the Human Gut Microbiome From Antibiotics Jean de Gunzburg,1,a Amine Ghozlane,2,a Annie Ducher,1,a Emmanuelle Le Chatelier,2,a Xavier Duval,3,4,5 Etienne Ruppé,2,b Laurence Armand-Lefevre,3,4,5
    [Show full text]
  • Effects of Ammonia on Gut Microbiota and Growth Performance of Broiler Chickens
    animals Article Effects of Ammonia on Gut Microbiota and Growth Performance of Broiler Chickens Hongyu Han, Ying Zhou, Qingxiu Liu, Guangju Wang, Jinghai Feng and Minhong Zhang * State Key Laboratory of Animal Nutrition, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China; [email protected] (H.H.); [email protected] (Y.Z.); [email protected] (Q.L.); [email protected] (G.W.); [email protected] (J.F.) * Correspondence: [email protected] Simple Summary: The composition and function of gut microbiota is crucial for the health of the host and closely related to animal growth performance. Factors that impact microbiota composition can also impact its productivity. Ammonia (NH3), one of the major contaminants in poultry houses, negatively affects poultry performance. However, the influence of ammonia on broiler intestinal microflora, and whether this influence is related to growth performance, has not been reported. Our results indicated that ammonia caused changes to cecal microflora of broilers, and these changes related to growth performance. Understanding the effects of ammonia on the intestinal microflora of broilers will be beneficial in making targeted decisions to minimize the negative effects of ammonia on broilers. Abstract: In order to investigate the influence of ammonia on broiler intestinal microflora and growth performance of broiler chickens, 288 21-day-old male Arbor Acres broilers with a similar weight were randomly divided into four groups with different NH3 levels: 0 ppm, 15 ppm, 25 ppm, and 35 ppm. The growth performance of each group was recorded and analyzed. Additionally, 16s rRNA Citation: Han, H.; Zhou, Y.; Liu, Q.; sequencing was performed on the cecal contents of the 0 ppm group and the 35 ppm group broilers.
    [Show full text]
  • Metabolome and Microbiota Analysis Reveals the Conducive Effect of Pediococcus Acidilactici BCC-1 and Xylan Oligosaccharides on Broiler Chickens
    fmicb-12-683905 May 23, 2021 Time: 14:38 # 1 ORIGINAL RESEARCH published: 28 May 2021 doi: 10.3389/fmicb.2021.683905 Metabolome and Microbiota Analysis Reveals the Conducive Effect of Pediococcus acidilactici BCC-1 and Xylan Oligosaccharides on Broiler Chickens Yuqin Wu1, Zhao Lei1, Youli Wang1, Dafei Yin1, Samuel E. Aggrey2, Yuming Guo1 and Jianmin Yuan1* 1 State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China, 2 NutriGenomics Laboratory, Department of Poultry Science, University of Georgia, Athens, GA, United States Xylan oligosaccharides (XOS) can promote proliferation of Pediococcus acidilactic BCC-1, which benefits gut health and growth performance of broilers. The study aimed to investigate the effect of Pediococcus acidilactic BCC-1 (referred to BBC) and XOS on the gut metabolome and microbiota of broilers. The feed conversion ratio of BBC group, XOS group and combined XOS and BBC groups was lower Edited by: than the control group (P < 0.05). Combined XOS and BBC supplementation (MIX Michael Gänzle, group) elevated butyrate content of the cecum (P 0.05) and improved ileum University of Alberta, Canada < morphology by enhancing the ratio of the villus to crypt depth (P 0.05). The 16S Reviewed by: < Richard Ducatelle, rDNA results indicated that both XOS and BBC induced high abundance of butyric Ghent University, Belgium acid bacteria. XOS treatment elevated Clostridium XIVa and the BBC group enriched Shiyu Tao, Huazhong Agricultural University, Anaerotruncus and Faecalibacterium. In contrast, MIX group induced higher relative China abundance of Clostridiaceae XIVa, Clostridiaceae XIVb and Lachnospiraceae. Besides, *Correspondence: MIX group showed lower abundance of pathogenic bacteria such as Campylobacter.
    [Show full text]
  • Parasutterella, in Association with Irritable Bowel Syndrome And
    Parasutterella, in associated with Irritable Bowel Syndrome and intestinal chronic inflammation Running head: Parasutterella may be related with IBS Authors: Yan-Jie Chen1, Hao Wu1, Sheng-Di Wu1, Nan Lu, Yi-Ting Wang, Hai-Ning Liu, Ling Dong, Tao-Tao Liu, Xi-Zhong Shen* Author address: Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China *Correspondences: Xi-Zhong Shen, MD, PhD, Department of Gastroenterology, Zhongshan Hospital of Fudan University, 180 Fenglin Rd., Shanghai 200032, China, Tel: +86-21-64041990-2070; Fax: +86-21-64038038. E-mail: [email protected] / [email protected] 1These authors contributed equally to this work. Acknowledgments The authors would like to express gratitude to the staff of Prof. Xi- Zhong Shen's laboratory for their critical discussion and reading of the manuscript. This study was supported by Youth Foundation of Zhongshan Hospital (No. 2015ZSQN08), Shanghai Sailing Program (No. 16YF1401500), Foundation of Shanghai Institute of Liver Diseases, and National Natural Science Foundation of China (No. 81101540; No. 81101637; No. 81172273; No. 81272388). Conflict of interest statement The authors declare that there are no conflicts of interest. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jgh.14281 This article is protected by copyright. All rights reserved. Abstract Background and Aim: Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal disorder.
    [Show full text]
  • The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment
    nutrients Review The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment Jonathan C. W. Liu 1,2 , Ilona Gorbovskaya 1,3, Margaret K. Hahn 1,2,3,4,5 and Daniel J. Müller 1,2,3,4,* 1 Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, ON M5T 1R8, Canada; [email protected] (J.C.W.L.); [email protected] (I.G.); [email protected] (M.K.H.) 2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada 3 Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada 4 Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada 5 Banting and Best Diabetes Centre, University of Toronto, ON M5G 2C4, Canada * Correspondence: [email protected] Abstract: The gut microbiome (GMB) plays an important role in developmental processes and has been implicated in the etiology of psychiatric disorders. However, the relationship between GMB and schizophrenia remains unclear. In this article, we review the existing evidence surrounding the gut microbiome in schizophrenia and the potential for antipsychotics to cause adverse metabolic events by altering the gut microbiome. We also evaluate the current evidence for the clinical use of probiotic and prebiotic treatment in schizophrenia. The current data on microbiome alteration in schizophrenia remain conflicting. Longitudinal and larger studies will help elucidate the confounding effect on the microbiome. Current studies help lay the groundwork for further investigations into the role of the GMB in the development, presentation, progression and potential treatment of schizophrenia.
    [Show full text]
  • Proteobacteria: Microbial Signature of Dysbiosis in Gut Microbiota
    Opinion Proteobacteria: microbial signature of dysbiosis in gut microbiota * * Na-Ri Shin , Tae Woong Whon , and Jin-Woo Bae Department of Life and Nanopharmaceutical Sciences and Department of Biology, Kyung Hee University, Seoul 130-701, Korea Recent advances in sequencing techniques, applied to duction of essential vitamins, intestinal maturation, and the study of microbial communities, have provided com- development of the immune system. The healthy adult pelling evidence that the mammalian intestinal tract human gut microbiota is known to be stable over time harbors a complex microbial community whose compo- [10,11]; however, diseases associated with metabolism and sition is a critical determinant of host health in the immune responses drive the microbial community to an context of metabolism and inflammation. Given that imbalanced unstable state. an imbalanced gut microbiota often arises from a sus- Here, we review studies that have explored the associa- tained increase in abundance of the phylum Proteobac- tions between an abundance of Proteobacteria in the micro- teria, the natural human gut flora normally contains only biota and the difficulty for the host of maintaining a a minor proportion of this phylum. Here, we review balanced gut microbial community. Based on this analysis, studies that explored the association between an abnor- we propose that an increased prevalence of the bacterial mal expansion of Proteobacteria and a compromised phylum Proteobacteria is a marker for an unstable micro- ability to maintain a balanced gut microbial community. bial community (dysbiosis) and a potential diagnostic cri- We also propose that an increased prevalence of Pro- terion for disease. teobacteria is a potential diagnostic signature of dysbio- sis and risk of disease.
    [Show full text]
  • A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial Muhammad N
    Published OnlineFirst November 26, 2019; DOI: 10.1158/1940-6207.CAPR-19-0325 CANCER PREVENTION RESEARCH | RESEARCH ARTICLE A Calcium-Rich Multimineral Intervention to Modulate Colonic Microbial Communities and Metabolomic Profiles in Humans: Results from a 90-Day Trial Muhammad N. Aslam1, Christine M. Bassis2, Ingrid L. Bergin3, Karsten Knuver1, Suzanna M. Zick4,5, Ananda Sen4,6, D. Kim Turgeon7, and James Varani1 ABSTRACT ◥ q P ¼ Aquamin is a calcium-, magnesium-, and multiple trace thetaYC ( YC; 0.0087). Treatment with calcium also element–rich natural product with colon polyp prevention produced a decline in total bacteria, but smaller than seen efficacy based on preclinical studies. The goal of this study with Aquamin, whereas no reduction was observed with was to determine the effects of Aquamin on colonic micro- placebo in the colon. In parallel with microbial changes, a bial community and attendant metabolomic profile. Thirty reduction in total bile acid levels (P ¼ 0.0375) and a slight healthy human participants were enrolled in a 90-day trial in increase in the level of the short-chain fatty acid (SCFA) which Aquamin (delivering 800 mg of calcium per day) was acetate in stool specimens (P < 0.0001) from Aquamin- compared with calcium alone or placebo. Before and after the treated participants were noted. No change in bile acids or intervention, colonic biopsies and stool specimens were SCFAs was observed with calcium or placebo. We conclude obtained. All 30 participants completed the study without that Aquamin is safe and tolerable in healthy human parti- serious adverse event or change in liver and renal function cipants and may produce beneficial alterations in the colonic markers.
    [Show full text]
  • Increasing Levels of Parasutterella in the Gut Microbiome Correlate With
    Increasing levels of Parasutterella in the gut microbiome correlate with improving Low-Density Lipoprotein levels in healthy adults consuming resistant potato starch during a randomised trial Jason Russell Bush ( [email protected] ) Brandon University https://orcid.org/0000-0002-6289-5191 Michelle J Alfa University of Manitoba Research article Keywords: Parasutterella, Proteobacteria, potato, resistant starch, LDL, cholesterol Posted Date: October 26th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-49977/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on December 11th, 2020. See the published version at https://doi.org/10.1186/s40795-020-00398-9. Page 1/17 Abstract Background: Prebiotics, dened as a substrate that is selectively utilized by host microorganisms conferring a health benet, present a potential option to optimize gut microbiome health. Elucidating the relationship between specic intestinal bacteria, prebiotic intake, and the health of the host remains a primary microbiome research goal. Objective: To assess the correlations between gut microbiota, serum health parameters, and prebiotic consumption in healthy adults. Methods: We performed ad hoc exploratory analysis of changes in abundance of genera in the gut microbiome of 75 participants from a randomized, placebo-controlled clinical trial that evaluated the effects of resistant potato starch (RPS; MSPrebiotic®, N = 38) intervention versus a fully digestible placebo (N = 37) for which primary and secondary outcomes have previously been published. Pearson correlation analysis was used to identify relationships between health parameters (ie. blood glucose and lipids) and populations of gut bacteria.
    [Show full text]